AI Summary & Key Takeaways
AI InsightThe overall well-being score of the patients as per the qualityof life findings was 46.18±11.66.
📌 3 Key Takeaways
Abstract
Objective: The aim of this study is to evaluate the symptoms experience and quality of life in patients with breast cancer receiving the taxane classof drugs.Materials and Methods: This study was performed between November 2015 March 2016 in a chemotherapy unit of a university hospital with48 patients, who agreed to participate in the study. The Memorial Symptom Rating Score (MSAS), Socio-demographic and Clinical Features Form,European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and European Organizationfor Research and Treatment of Cancer Quality of Life Questionnaire-Breast (EORTC QLQ- BR23) measures specific to breast cancer were used toobtain data.Results: The average age of the patients was 45.65. The majority of patients were treated with the paclitaxel/paclitaxel+trastuzumab treatment protocol (60.42%), and more than half (54.16%) of these patients were on 5 or 6 treatments. The symptoms patients experienced the most commonlyincluded being sensitive, weakness or energy loss and pain. The symptoms they experienced severely were included fatigue and energy loss and beingsensitive. The most distressing symptoms were pain, worry, numbness in hands and feet. The overall well-being score of the patients as per the qualityof life findings was 46.18±11.66. While the lowest score for the functional scales was in the social function subscale (66.32±15.18), the highest scorefor the symptom scales was in the pain subscale (42.01±15.37). The lowest score for the EORTC QLQ-BR23 scales was in the sexual life subscale(20.83±20.19); the highest score was in the body appearance subscale (65.8±23.96).Conclusion: The results of the study are thought to be helpful for the oncology nurses in evaluating the patients in all aspects and in determiningpriorities for care.